000538 云南白药
已收盘 08-11 15:00:00
资讯
新帖
简况
云南白药：8月11日接受机构调研，包括知名机构盘京投资的多家机构参与
证券之星 · 08-11 22:32
云南白药：8月11日接受机构调研，包括知名机构盘京投资的多家机构参与
云南白药：健康品事业群在未来发展中，将继续发挥品牌全渠道的协同能力
证券日报网 · 08-11 21:32
云南白药：健康品事业群在未来发展中，将继续发挥品牌全渠道的协同能力
云南白药：2025年，云南白药气雾剂和膏贴等核心系列产品销售收入总额超过55亿元
证券日报网 · 08-11 21:32
云南白药：2025年，云南白药气雾剂和膏贴等核心系列产品销售收入总额超过55亿元
股市必读：云南白药（000538）8月7日董秘有最新回复
证券之星 · 08-10 02:41
股市必读：云南白药（000538）8月7日董秘有最新回复
云南白药：气血康口服液改善心脏和血管健康的临床研究项目论文已在《转化内科学杂志》发表
证券之星 · 08-07
云南白药：气血康口服液改善心脏和血管健康的临床研究项目论文已在《转化内科学杂志》发表
云南白药：持续夯实内在价值，多措并举提升股东回报
证券之星 · 08-07
云南白药：持续夯实内在价值，多措并举提升股东回报
云南白药：经营业绩逆势增长
证券之星 · 08-07
云南白药：经营业绩逆势增长
云南白药获得发明专利授权：“一种多孔二氧化硅及其应用”
证券之星 · 08-05
云南白药获得发明专利授权：“一种多孔二氧化硅及其应用”
研报掘金丨财信证券：首予云南白药“增持”评级，加快培育第二增长曲线
格隆汇 · 07-28
研报掘金丨财信证券：首予云南白药“增持”评级，加快培育第二增长曲线
云南白药：7月22日接受机构调研，广发证券、国联民生证券等多家机构参与
证券之星 · 07-22
云南白药：7月22日接受机构调研，广发证券、国联民生证券等多家机构参与
云南白药：2025年公司在泰国生产的首批牙膏正式下线
证券之星 · 07-17
云南白药：2025年公司在泰国生产的首批牙膏正式下线
股市必读：7月7日云南白药现497.2万元大宗交易
证券之星 · 07-08
股市必读：7月7日云南白药现497.2万元大宗交易
云南白药获得外观设计专利授权：“药品包装盒（气血康口服液）”
证券之星 · 07-03
云南白药获得外观设计专利授权：“药品包装盒（气血康口服液）”
科捷物流连续拿下云南白药双项目，打造 B2B+B2C 一体化仓配标杆
智通财经 · 06-30
科捷物流连续拿下云南白药双项目，打造 B2B+B2C 一体化仓配标杆
云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目
智通财经 · 06-24
云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目
云南白药：公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力
证券日报网 · 06-04
云南白药：公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力
云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可
智通财经 · 06-03
云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可
云南白药（000538）披露董事会审议通过向参股公司推荐董事候选人议案，5月21日股价下跌1.28%
证券之星 · 05-21
云南白药（000538）披露董事会审议通过向参股公司推荐董事候选人议案，5月21日股价下跌1.28%
云南白药(000538)3月31日股东户数16.93万户，较上期减少9.01%
证券之星 · 04-30
云南白药(000538)3月31日股东户数16.93万户，较上期减少9.01%
云南白药：公司没有您所提及的合作
证券之星 · 04-30
云南白药：公司没有您所提及的合作
加载更多
公司概况
公司名称：
云南白药集团股份有限公司
所属行业：
医药制造业
上市日期：
1993-12-15
主营业务：
云南白药集团股份有限公司的主营业务是药品、健康品、中药资源的研发、生产及销售。公司的主要产品是工业产品（自制）、批发零售。2025年，云南白药第16年上榜财富中文网发布的《财富中国500强排行榜》，位列第357位；入选美国《制药经理人》杂志《全球制药企业50强排行榜》，位列第33位。
发行价格：
3.38
{"stockData":{"symbol":"000538","market":"SZ","secType":"STK","nameCN":"云南白药","latestPrice":50.83,"timestamp":1786431834000,"preClose":51.19,"halted":0,"volume":8499314,"delay":0,"changeRate":-0.007,"floatShares":1773000000,"shares":1784000000,"eps":2.9459,"marketStatus":"已收盘","change":-0.36,"latestTime":"08-11 15:00:00","open":51.01,"high":51.43,"low":50.8,"amount":434000000,"amplitude":0.0123,"askPrice":50.83,"askSize":8,"bidPrice":50.82,"bidSize":9,"shortable":0,"etf":0,"ttmEps":2.9459,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":5,"adr":0,"adjPreClose":51.19,"symbolType":"stock","openAndCloseTimeList":[[1786411800000,1786419000000],[1786424400000,1786431600000]],"highLimit":56.31,"lowLimit":46.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1784262603,"isCdr":false,"pbRate":2.17,"roa":"--","peRate":17.254489,"roe":"4.96%","epsLYR":2.89,"committee":0.134263,"marketValue":90694000000,"turnoverRate":0.0048,"status":1,"floatMarketCap":90118000000},"requestUrl":"/m/hq/s/000538/","defaultTab":"news","newsList":[{"id":"2658919512","title":"云南白药：8月11日接受机构调研，包括知名机构盘京投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658919512?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:32","pubTimestamp":1786458755,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年8月11日云南白药发布公告称公司于2026年8月11日接受机构调研，中金公司朱言音、盘京投资曹姗姗、深圳红筹投资王之栋、平安基金陶然、博时基金杨涛参与。云南白药2026年一季报显示，一季度公司主营收入116.03亿元，同比上升7.02%；归母净利润20.37亿元，同比上升5.31%；扣非净利润19.65亿元，同比上升4.12%；负债率25.31%，投资收益2.43亿元，财务费用1138.96万元，毛利率30.63%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0187","BK0028","BK0239","000538","LU1993786604.SGD","LU1960683339.HKD","BK0196","BK0164","BK0012","LU1807302812.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919320","title":"云南白药：健康品事业群在未来发展中，将继续发挥品牌全渠道的协同能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919320","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658919320?lang=zh_cn&edition=full","pubTime":"2026-08-11 21:32","pubTimestamp":1786455120,"startTime":"0","endTime":"0","summary":"证券日报网8月11日讯，云南白药在接受调研时表示，2025年，健康品事业群在保持线下渠道竞争优势的同时，通过场景化营销、功效科普种草、短直联动转化等方式，在内容电商、货架电商、即时零售领域发力，带动线上销售同比增长27%。健康品事业群在未来发展中，将继续发挥品牌全渠道的协同能力，通过分渠道分产品精细化运营，针对即时零售、内容电商、仓储会员店等增量渠道保持高度关注，坚持大胆试新、小步快跑的模式寻找增量，同时也通过研发创新，加速产学研平台的产品转化，积极培育新的增长点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkh5705366.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkh5705366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","LU1993786604.SGD","LU1807302812.USD","BK0175","BK0028","BK0012","BK0239","LU1960683339.HKD","BK0196","BK0187","000538","BK0164"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658376919","title":"云南白药：2025年，云南白药气雾剂和膏贴等核心系列产品销售收入总额超过55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658376919","media":"证券日报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658376919?lang=zh_cn&edition=full","pubTime":"2026-08-11 21:32","pubTimestamp":1786455120,"startTime":"0","endTime":"0","summary":"证券日报网8月11日讯，云南白药在接受调研时表示，2025年，云南白药气雾剂和膏贴等核心系列产品销售收入总额超过55亿元，较去年同期增长超18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkh5705370.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-11/doc-inimyhkh5705370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0012","BK0028","BK0239","BK0196","LU1807302812.USD","LU1993786604.SGD","BK0187","LU1960683339.HKD","BK0164","000538","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658576608","title":"股市必读：云南白药（000538）8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658576608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658576608?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:41","pubTimestamp":1786300870,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，云南白药报收于50.76元，上涨0.14%，换手率0.53%，成交量9.47万手，成交额4.79亿元。股价以长期低迷恳请管理层重视。目前，以云南白药自有基地认证品种共有3个，分别为重楼、当归、红花，面积达898亩，合作共建GAP基地面积3695亩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1993786604.SGD","BK0028","BK0164","000538","BK0188","BK0012","LU1807302812.USD","LU1960683339.HKD","BK0196","BK0239","BK0187","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611197","title":"云南白药：气血康口服液改善心脏和血管健康的临床研究项目论文已在《转化内科学杂志》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657611197?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:36","pubTimestamp":1786095368,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药08月07日在投资者关系平台上答复投资者关心的问题。有三个问题：1，气血康作为OTC产品，什么时候可以在广告营销上加上改善血管健康方面的内容？2，最近大火的张雪曾在访谈中提到涂了云南白药效果很好。3，最近董路率领的足球小将取得了成功。气血康口服液改善心脏和血管健康的临床研究项目论文《Effectiveness and safety of Qixuekang Oral Liquid on vascular health》已在《转化内科学杂志》发表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1807302812.USD","BK0175","BK0164","BK0012","000538","BK0239","BK0188","BK0028","LU1993786604.SGD","LU1960683339.HKD","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611515","title":"云南白药：持续夯实内在价值，多措并举提升股东回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657611515?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:33","pubTimestamp":1786095192,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药08月07日在投资者关系平台上答复投资者关心的问题。云南白药长期投资价值突出，当前股价波动主要受宏观市场环境、市场资金偏好等外部因素影响，存在一定不确定性。公司高度重视市值管理工作，持续夯实内在价值，保持战略定力，强化业务聚焦，寻求系统突破，卓越运营管理，构建共赢格局，多措并举提升股东回报，以切实的经营成果回馈广大投资者，提升投资者获得感。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0239","BK0188","BK0012","BK0196","LU1807302812.USD","LU1960683339.HKD","BK0175","000538","BK0164","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061155","title":"云南白药：经营业绩逆势增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657061155?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:33","pubTimestamp":1786095187,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药08月07日在投资者关系平台上答复投资者关心的问题。公司有足够的现金，为何在股价这么低的时候不采取回购的措施，是对公司的发展没有信心吗云南白药回复：您好！云南白药长期投资价值突出，当前股价波动主要受宏观市场环境、市场资金偏好等外部因素影响，存在一定不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","LU1807302812.USD","BK0187","BK0175","BK0012","BK0239","000538","LU1993786604.SGD","BK0028","BK0188","LU1960683339.HKD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696395","title":"云南白药获得发明专利授权：“一种多孔二氧化硅及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657696395?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:52","pubTimestamp":1785873178,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示云南白药新获得一项发明专利授权，专利名为“一种多孔二氧化硅及其应用”，专利申请号为CN202410625618.0，授权日为2026年8月4日。今年以来云南白药新获得专利授权16个，较去年同期减少了15.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500005929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0239","BK0188","BK0012","BK0196","LU1807302812.USD","LU1960683339.HKD","BK0175","000538","BK0164","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654073028","title":"研报掘金丨财信证券：首予云南白药“增持”评级，加快培育第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2654073028","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654073028?lang=zh_cn&edition=full","pubTime":"2026-07-28 13:44","pubTimestamp":1785217445,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0012","LU1960683339.HKD","BK0187","BK0239","BK0188","LU1993786604.SGD","BK0175","161027","BK0196","LU1807302812.USD","000538","BK0164","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653576662","title":"云南白药：7月22日接受机构调研，广发证券、国联民生证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2653576662","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653576662?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:30","pubTimestamp":1784730654,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月22日云南白药发布公告称公司于2026年7月22日接受机构调研，广发证券李桠桐、国联民生证券乐妍希、财通资管杨佳睿、华泰资管朱南钰、海富通赵晨凯、保银邹舟、东吴自营滕越、中邮资管孙鹏参与。云南白药胶囊治疗踝关节周围骨折肢体肿胀临床多中心试验研究已入组36例。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1934453819.USD","BK0276","601456","BK0164","BK0028","01456","BK0188","BK0239","LU1993786604.SGD","BK0187","SG9999001093.SGD","000776","000538","01776","BK0012","BK1147","LU1979443071.USD","BK0175","LU1960683339.HKD","LU1807302812.USD","BK1564","BK0196","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409296","title":"云南白药：2025年公司在泰国生产的首批牙膏正式下线","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409296","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652409296?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:18","pubTimestamp":1784279887,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘：公司年度报告显示，2025年公司主营收入仍全部在国内实现，这太让人失望了。按照云南白药的品牌影响力，公司走出去很难吗？2025年公司在泰国生产的首批牙膏正式下线，实现境外生产零的突破；完成马来西亚、印尼等多国产品注册，构建药品+健康品双轮驱动的全球注册体系。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700031603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000538","BK0175","BK0187","LU1993786604.SGD","LU1807302812.USD","BK0188","BK0028","BK0239","LU1960683339.HKD","BK0164","BK0196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934507","title":"股市必读：7月7日云南白药现497.2万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649934507?lang=zh_cn&edition=full","pubTime":"2026-07-08 01:49","pubTimestamp":1783446550,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，云南白药报收于48.65元，下跌1.28%，换手率0.41%，成交量7.2万手，成交额3.5亿元。当日关注点交易信息汇总：7月7日云南白药主力资金净流出1317.82万元。交易信息汇总：7月7日云南白药发生497.2万元大宗交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","BK0187","LU1807302812.USD","BK0028","BK0164","LU1993786604.SGD","BK0012","BK0239","LU1960683339.HKD","000538","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648804676","title":"云南白药获得外观设计专利授权：“药品包装盒（气血康口服液）”","url":"https://stock-news.laohu8.com/highlight/detail?id=2648804676","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648804676?lang=zh_cn&edition=full","pubTime":"2026-07-03 03:27","pubTimestamp":1783020443,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示云南白药新获得一项外观设计专利授权，专利名为“药品包装盒”，专利申请号为CN202530764607.6，授权日为2026年7月3日。今年以来云南白药新获得专利授权14个，较去年同期增加了16.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300004812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","LU1960683339.HKD","LU1807302812.USD","BK0187","BK0196","BK0188","BK0175","BK0164","BK0028","000538","BK0239","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647958209","title":"科捷物流连续拿下云南白药双项目，打造 B2B+B2C 一体化仓配标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2647958209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647958209?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:55","pubTimestamp":1782798915,"startTime":"0","endTime":"0","summary":"近期，科捷物流再传佳音，再度中标云南白药集团股份有限公司及旗下子公司物流运输服务项目，服务云南白药健康品类、药品类、食品保健品、中药材等产品的物流运输服务，负责部分线路的运输服务，该项目目前已完成上线，运营状况平稳。谈及本次合作，科捷物流相关负责人表示，连续中标云南白药两大项目，是公司全渠道一体化仓配服务能力的有力印证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1155","LU1807302812.USD","BK0028","BK0188","00861","BK0196","LU0348825331.USD","000538","BK0239","LU1993786604.SGD","BK0164","BK0012","BK0175","BK0187","LU0417516902.SGD","LU1960683339.HKD","BK1586"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891421","title":"云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891421","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645891421?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:53","pubTimestamp":1782294820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布公告，公司董事会审议通过《关于建设无锡药业经皮给药技术产业平台项目的议案》，公司全资子公司云南白药集团无锡药业有限公司将建设无锡药业经皮给药技术产业平台项目，该项目投资总预算为3.6亿元，项目规划核心成熟产品保供、创新升级产品落地、新型剂型研发储备三大产品管线，全面覆盖伤科核心品类深耕、高端透皮制剂拓展、创新剂型孵化全维度需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云南白药(000538.SZ)拟投资3.6亿元建设无锡药业经皮给药技术产业平台项目","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0164","LU1807302812.USD","BK0028","BK0188","BK0239","LU1960683339.HKD","BK0012","BK0196","BK0175","LU1993786604.SGD","000538"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640733163","title":"云南白药：公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2640733163","media":"证券日报网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640733163?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:02","pubTimestamp":1780581720,"startTime":"0","endTime":"0","summary":"证券日报网6月4日讯，云南白药在接受调研者提问时表示，公司将继续坚持战略性投资并购方向，持续提升对并购标的的专业研判与筛选能力，重点遴选与云南白药品牌定位、产品矩阵、渠道网络及核心竞争优势高度协同的标的，集中优势资源推动战略性并购突破，切实补强业务发展动能。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-04/doc-iniahhrk0190338.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-04/doc-iniahhrk0190338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0012","BK0187","000538","BK0196","BK0164","BK0175","LU1807302812.USD","LU1960683339.HKD","LU1993786604.SGD","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640004908","title":"云南白药(000538.SZ)：INB301注射液获美国FDA新药临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2640004908","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640004908?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:57","pubTimestamp":1780480643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云南白药(000538.SZ)发布公告，公司于近日收到美国食品药品监督管理局(简称“美国FDA”)的通知，由公司申报的INB301注射液新药临床试验申请(简称“IND”)已获得美国FDA许可，同意开展临床试验，拟开发适应症为肿瘤恶病质。该药品为公司研发的首个治疗用生物创新药，拟用于治疗肿瘤恶病质。肿瘤恶病质是一种由恶性肿瘤引发的复杂代谢紊乱综合征，以持续性骨骼肌消耗为特征，常规营养支持难以逆转。截至目前，已获得中美两国临床试验许可，累计已投入研发费用约人民币5066.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","LU1807302812.USD","BK0187","BK0175","BK0012","BK0239","000538","BK4588","LABU","LU1993786604.SGD","BK0028","BK0188","BK4585","LU1960683339.HKD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637016334","title":"云南白药（000538）披露董事会审议通过向参股公司推荐董事候选人议案，5月21日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637016334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637016334?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:14","pubTimestamp":1779372858,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，云南白药报收于50.13元，较前一交易日下跌1.28%，最新总市值为894.45亿元。该股当日开盘50.86元，最高50.88元，最低50.12元，成交额达3.46亿元，换手率为0.39%。近日，云南白药集团股份有限公司披露《第十一届董事会2026年第四次会议决议公告》。会议审议通过《关于向参股公司推荐董事候选人的议案》，表决结果为12票同意、0票反对、0票弃权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000538","BK0175","BK0164","LU1993786604.SGD","BK0187","BK0196","BK0239","BK0012","LU1960683339.HKD","BK0188","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631168497","title":"云南白药(000538)3月31日股东户数16.93万户，较上期减少9.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631168497","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631168497?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:37","pubTimestamp":1777541827,"startTime":"0","endTime":"0","summary":"证券之星消息，近日云南白药披露，截至2026年3月31日公司股东户数为16.93万户，较12月31日减少1.68万户，减幅为9.01%。在中药行业个股中，云南白药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.39万户。从股价来看，2025年12月31日至2026年3月31日，云南白药区间跌幅为3.35%，在此期间股东户数减少1.68万户，减幅为9.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000056740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0187","LU1993786604.SGD","LU1807302812.USD","BK0175","BK0188","BK0164","LU1960683339.HKD","BK0012","BK0239","000538"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631685904","title":"云南白药：公司没有您所提及的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2631685904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631685904?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:18","pubTimestamp":1777537102,"startTime":"0","endTime":"0","summary":"证券之星消息，云南白药(000538)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：1. 药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。请问贵司在管线研发中，是否与药石科技有合作？未来是否有计划在早期化合物发现、工艺开发或商业化生产层面开展合作？云南白药回复：您好！公司没有您所提及的合作，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1993786604.SGD","BK0028","LU1960683339.HKD","BK0187","BK0175","BK0012","BK0188","000538","LU1807302812.USD","BK0164","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786479005689,"stockEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":0.0412},{"period":"3month","weight":-0.0159},{"period":"6month","weight":-0.0775},{"period":"1year","weight":-0.0487},{"period":"ytd","weight":-0.0778}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0727},{"period":"6month","weight":-0.0484},{"period":"1year","weight":0.0786},{"period":"ytd","weight":-0.0088}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南白药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"169274人(较上一季度减少9.01%)","perCapita":"10473股","listingDate":"1993-12-15","address":"云南省昆明市呈贡区云南白药街3686号","registeredCapital":"178426万元","survey":" 云南白药集团股份有限公司的主营业务是药品、健康品、中药资源的研发、生产及销售。公司的主要产品是工业产品（自制）、批发零售。2025年，云南白药第16年上榜财富中文网发布的《财富中国500强排行榜》，位列第357位；入选美国《制药经理人》杂志《全球制药企业50强排行榜》，位列第33位。","listedPrice":3.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云南白药(000538)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云南白药(000538)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云南白药,000538,云南白药股票,云南白药股票老虎,云南白药股票老虎国际,云南白药行情,云南白药股票行情,云南白药股价,云南白药股市,云南白药股票价格,云南白药股票交易,云南白药股票购买,云南白药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云南白药(000538)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云南白药(000538)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}